Articles tagged "Rejection"

2016 American Transplant Congress
Outcomes with Steroids Alone for Biopsy-Proven Pancreas Transplant Rejection.
S. Salahuddin,¹ B. Astor,¹ S. Parajuli,¹ A. Djamali,¹ J. Odorico,² D. Mandelbrot.¹
¹Department of Nephrology, University of Wisconsin, Madison, WI; ²Department of Surgery, University of Wisconsin, Madison, WI.
There is little published data on the response of pancreas rejection to steroids alone. We reviewed 42 pancreas transplant recipients between 01/1997 and 12/2013 at…
2016 American Transplant Congress
Continuous Antithymocyte Globulin (rATG) for Treatment of Renal Allograft Rejection: Preliminary Analysis of a Prospective, Randomized Trial.
S. Patel, R. Knight, S. Kuten, J. Nolte, A. Gaber.
Houston Methodist Hospital, Houston, TX.
Intravenous (IV) rATG for acute rejection (AR) is primarily given on an inpatient basis due to its daily administration, IV access requirement, and monitoring. The…
2016 American Transplant Congress
CD45RO+/CD62L- Effector Memory T Cells Mediate Depletion Resistant Allograft Rejection in Intestinal Transplant Recipients.
C. Cosentino, J. Kaiser, A. Shukla, C. Desai, R. Girlanda, J. Hawksworth, C. Matsumoto, M. Zasloff, T. Fishbein, A. Kroemer.
MedStar Georgetown Transplant Institute, Washington DC.
A. A high risk of acute cellular rejection (ACR) is one of the key factors limiting intestinal transplantation (ITx). An extremely poor prognosis is related…
2016 American Transplant Congress
Frequency and Utility of Donor-Specific Antibody Testing in Simultaneous Liver Kidney Transplant.
A. Morrison,¹ D. Sawinski,² M. Kamoun,³ P. Porrett.¹
¹Surgery, University of Pennsylvania, Philadelphia, PA; ²Medicine, University of Pennsylvania, Philadelphia, PA; ³Pathology, University of Pennsylvania, Philadelphia, PA.
Introduction: The risk of antibody mediated rejection (AMR) in simultaneous liver kidney (SLK) recipients is thought to be lower than in kidney alone patients due…
2016 American Transplant Congress
Tocilizumab as Treatment for Persistent Chronic Active Antibody Mediated Rejection.
H. Fernandez, S. Patel, M. Chiles, L. Ratner, R. Crew.
Columbia University Medical Center, NYC.
Intro: CAAMR is an increasingly recognized cause of renal allograft failure with limited treatment options. Many patients with CAAMR have engagement of both T and…
2016 American Transplant Congress
Influence of Country-Associated Geographical Variables in the Ouctomes of Kidney Transplantation in Patients with HIV-Infection.
M. Cristelli,¹ F. Cofán,² H. Tedesco-Silva,¹ J. Trullas,³ D. Santos,¹ C. Manzardo,⁴ F. Aguero,⁴ A. Moreno,⁴ F. Oppenheimer,² F. Dieckmann,¹ J. Miro,⁴ J. Medina-Pestana.¹
¹Hospital do Rim-UNIFESP, São Paulo, Brazil; ²Nephrology, Hospital Clinic-IDIBAPS, Barcelona, Spain; ³Hospital de Olot, Girona, Spain; ⁴Infectology, Hospital Clinic-IDIBAPS, Barcelona, Spain.
Objective: To evaluate effects of geographical factors on demography, clinical management and evolution of two cohorts of HIV-infected KT recipients.Methods: Observational, retrospective cohort study including…
2016 American Transplant Congress
Factors Mediating Kidney Rejection in Patients of Simultaneous Liver-Kidney Transplants.
R. Dong, A. Tambur, L. Gallon, J. Levitsky.
Northwestern, Chicago, IL.
BACKGROUND & AIM: Kidney grafts in simultaneous liver-kidney (SLK) recipients are considered to be immunologically protected due to hepatic tolerance, although recent studies have alternatively…
2016 American Transplant Congress
Benefit of Protocol Biopsies in Pediatric Kidney Transplant Patients.
M. Nazario, O. Moussa, S. Self, K. Twombley.
Medical University of South Carolina, Charleston.
BackgroundMuch debate exists over the utility of protocol biopsies for pediatric kidney transplant recipients. While there is a growing amount of literature on the utility…
2016 American Transplant Congress
First Clinical Experience with Belatacept in 3 Hand Transplanted Patients.
J. Grahammer,¹ B. Zelger,² B. Zelger,³ M. Ninkovic,¹ A. Muehlbacher,⁴ D. Oefner-Velano,¹ S. Schneeberger,¹ A. Weissenbacher.⁵
¹Viceral, Thoracic and Transplant Surgery, Innsbruck Medical University, Innsbruck, Austria; ²Dermatology and Venerology, Innsbruck Medical University, Innsbruck, Austria; ³Pathology, Innsbruck Medical University, Innsbruck, Austria; ⁴Department of Blood Group Serology and Transfusion Medicine, Innsbruck Medical University, Innsbruck, Austria; ⁵Oxford Transplant Centre, Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom.
Study purposeBelatacept (CTLA4Ig) is an emerging treatment in solid organ transplantation. Effects on the development of donor specific antibodies (DSA) as well as its clinical…
2016 American Transplant Congress
DEPTOR Inhibits mTORC1 in CD4⁺ T Cells and Increases Treg Function by Stabilizing Foxp3 Expression.
J. Wedel,^1,2 S. Bruneau,^1,2 D. Briscoe.^1,2
¹Division of Nephrology, Boston Children's Hospital, Boston, MA; ²Transplant Research Program, Harvard Medical School, Boston, MA.
The modulation of PI-3K/Akt-induced signaling is critical for CD4+ Treg homeostasis and stability. Moreover, activation of PI-3K/Akt/mTOR signals within T cell subsets is associated with…